Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) released financial report for the fourth quarter of FY2016. Total revenues in 4Q2016 surged to $831 million, a 19% jump compared to the same quarter in FY2015. The negative effect of foreign currency on revenue in the reported quarter was 2% or $12 million.
On a GAAP basis, EPS for 4Q2016 was $0.41 per share, as against $0.29 per share in the same quarter of 2015. However, non-GAAP diluted EPS came at $1.26 per share compared to $1.04 a share in the same quarter of 2015, highlighting a decline of $0.09 per share to agree to the existing non-GAAP income tax cost definition. Both non-GAAP and GAAP results are inclusive of accounting, legal and other expenses linked with the Audit & Finance Committee’s closed investigation.
David Brennan, the Interim CEO of Alexion, reported that in FY2016 the international team of company delivered on patient-centered goals as they grew their leadership in balance by serving increased number of patients with aHUS and PNH, and continued to establish their metabolic franchise with the international releases of Kanuma and Strensiq.
They also achieved vital regulatory achievements towards fresh indications for Soliris and commenced two registration trials for ALXN1210 to lead their future growth. The 2017 guidance indicates double-digit EPS and revenue growth as they continue to grow their metabolic and complement franchises, prepare for the prospective releases of Soliris in refractory gMG, and concentrate on their highest priority Research & Development plans.
Total revenues for FY2016 of this biotech stock came at $3.084 billion, an 18% jump over FY2015. The negative effect of foreign currency on revenue YoY was 3% percent or $74 million. On a GAAP basis, EPS for FY2016 was $1.76 a share, as against to $0.67 per share in FY2015. Alexion reported that its Board has increased the size of the firm’s share repurchase authorization to $1 billion.